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Abstract
Introduction: Treatments of retinoic acid, a metabolite of vitamin A (VA) are shown to
induce hyperlipidemia in humans and animals, which may influence adiposity.

To

understand the role of VA in weight management, two studies, one in animals examining
effects of VA combined with high-fat diet (HFD) on body mass (BM) gain and the second
in humans comparing dietary VA between participants who were overweight/obese and
who had and had not lost 10% of body weight by consuming a hypocaloric, low-fat diet,
were conducted.
Methods: Male Sprague Dawley rats were fed a HFD containing sufficient VA (HF-VAS)
or a HFD deficient in VA (HF-VAD) for eight weeks. BM, liver mass, white adipose mass,
brown adipose mass and plasma glucose were measured. The groups were compared
with student's t-test. For the second experiment, participants (51.9 ± 8.8 yrs, 35.0 + 4.5
kg/m2, 94.7% white, 59.6% female, 100% non-hispanic) in a lifestyle intervention were
categorized as successful weight losers (loss of > 10% body weight) or unsuccessful
weight losers (loss of < 10% body weight) after 6 months of treatment on a hypocaloric,
low-fat diet. Dietary intake, assessed by three, 24-hour dietary recalls was collected at 6
months. Dietary VA was compared between the groups using analysis of covariance.
Results: In the animal study, significant differences were detected in end day BM, liver
mass and white adipose mass between the HF-VAS and HFD-VAD groups.

No

significant difference was detected in dietary VA consumed between participants who had
successful 10% weight loss and those who did not have successful weight loss at 6
months.
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Conclusion: Results from the animal experiment indicate that VA plays a role in adiposity
in subjects consuming an obesogenic diet. No difference was detected in VA intake
between subjects who successfully lost 10% weight and those who have not. This
indicates dietary VA is not related to successful weight loss on a hypocaloric, low-fat diet.
Additional studies are needed to understand the role VA plays in obesity development.
Also, further investigation on how VA intake while consuming a hypocaloric low fat diet
may affect weight loss is needed.
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Introduction
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1.1 Background
Obesity, defined as excessive body fat content indicated by a BMI ≥ 30 kg/m2,
continues to be a nationwide problem with one third of Americans considered to be
obese1.

This epidemic predicts the development of various metabolic diseases 2,

resulting in higher mortality rates and higher costs in health care3. Aside from this, obesity
has been linked to decreased productivity in the workplace, which can indirectly increase
healthcare costs3. The increases in mortality rates and costs of health care have become
an urgent problem, which finding solutions must become priority.
Obesity is thought to be caused by positive energy balance, meaning that energy
intake is greater than energy output4. Both genetic and environmental factors contribute
to the development of obesity and its associated chronic metabolic diseases. Several
genes, such as leptin and its receptor, responsible for monogenic obesity have been
identified5. On the other hand, over nutrition seems to be an obvious cause of obesity
development. However, the role of each micronutrient has not been revealed. Previous
research indicates that VA may also play a role in the development of obesity6. This
thesis includes two parts. The first one aims to investigate the contributions of VA intake
on obesity development in rats fed a high-fat diet (HFD). The second portion studied the
effects of VA intake on body weight alterations in participants during a hypocaloric, lowfat diet. The project seeks to answer the following questions: Does the presence of VA
in the diet have an effect on weight gain while subjects are consuming a high-fat
obesogenic diet? Is there a significant difference in the amount of dietary VA consumed
by partcipants who successfully lost weight while consuming a hypocaloric, low-fat diet
compared to those who did not in a clinical weight loss trial? The two experiments use

3
different models to answer the questions. The first experiment uses an animal model
looking at weight gain on a high-fat diet, while the second experiment uses a human
model looking at weight loss on a hypocaloric, low-fat diet.
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Chapter II
Literature Review
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2.1 Vitamin A (VA) and its homeostasis
2.1.1 The discovery of VA and provitamin A
VA, all-trans retinol ((2E, 4E, 6E, 8E)- 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1enyl) nona-2,4,6,8-tetraen-1-ol)),

is a lipid soluble vitamin which exists in multiple

isomeric forms7. All of these forms contain a 20 carbon structure with a methyl substituted
cyclohexenyl ring and a tetraene side chain differing in the molecules attached to this side
chain7. It was first identified in 1910s and later elucidated in 1930s as a lipid derived
factor essential for the growth of animals8,9.
VA activity was observed when rats fed a synthetic diet with lard or olive oil
extracted with ether as the only fat source would lose weight and then die. In contrast,
rats given certain lipid derived factors from foods such as eggs and butter survived and
began to grow again10. Later on, its molecular identity as retinol was determined. VA
activity can be derived from molecules that can be converted into retinol 11. In the diet,
these molecules are retinol esters (animal sources) and provitamin A carotenoids (plant
sources)12. The majority of VA physiological activities are mediated by RA13. Retinol (an
alcohol) is first reversibly oxidized into retinal (an aldehyde), and then irreversibly oxidized
into RA. It has been recognized for its role as essential micronutrient for the general health
of the individual. In the body, VA is essential for vision, growth, skin development and
cell differentiation14.
2.1.2 The discovery of carotenoids
Carotenoids were discovered as a result of the search for a medicinal agent, an
anthelminthic to rid the body of parasitic worms, especially from the intestine 15. Credit
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for this discovery goes to Heinrich Wilhelm Ferdinand Wackenroder15. He published the
results of his examination of carrots, with one of the purposes of that research being the
search for the presence in the juice of the carrots of an effective anthelminthic15. This
prompted Wackenroder to undertake chemical analysis of the juice in the attempt to
identify the substance that was medically active15. The results of this work were
published in 183115.
In humans, three carotenoids (beta-carotene, alpha-carotene, and betacryptoxanthin) have VA activity, and these and other carotenoids can also act as
antioxidants10. In the body, provitamin A carotenoids are cleaved to form retinal, which
is then reduced to retinol12.
2.1.3 VA metabolism and its active metabolic intermediates
Retinol, the least potent form of molecules with VA activities, contains a hydroxyl
group at carbon-15. Retinol can act as a precursor for the more active forms of molecules
with VA activities. When retinol is oxidized to retinal the molecule contains an aldehyde
group, which is further oxidized to RA containing a carboxylic acid group7. VA activity
can be derived from molecules that can be converted into retinol 11. The majority of VA
activities are mediated by RA13.
Enzymes responsible for the reversible oxidation/reduction reaction of retinol to
retinal are termed dehydrogenases and exhibit properties as an alcohol dehydrogenase
or a short- chain dehydrogenase reductase16. Enzymes facilitating the irreversible
oxidation of retinal to RA are classified in the aldehyde dehydrogenase family16.
Cytochrome P450 hydroxylase 26A (CYP26A) mediates modification of RA molecules to
facilitate RA disposal. It is the primary CYP26 enzyme expressed in the liver, contributing
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the largest amount of activity in the clearance of RA from humans17. This gene irreversibly
oxidizes RA into more polar metabolites for excretion17.
2.1.4 The conversion of carotenoids to VA
Of all known carotenoids, β-carotene is believed to be the most important in human
nutrition18. The key step in the VA biosynthetic pathway is the oxidative cleavage of βcarotene

into

two

retinal

molecules

by

the

enzyme

β,β-carotene-15,15′-

monooxygenase18. Subsequent oxidation yields retinoic acid which can then act as ligand
for nuclear transcription factors. Beta-carotene can also undergo eccentric cleavage
which can occur enzymatically or non-enzymatically19. This produces beta-apocarotenals
and beta-apocarotenones, whose functions in mammals are unknown19.
2.1.5 Digestion, absorption and storage of VA and carotenoids
Dietary VA comes from retinyl esters (animal sources) and provitamin A
carotenoids (plant sources)20. Carotenoids consist of 40 carbons, conjugated double
bonds, and may contain 1-2 cyclic structures at the end of their chain7. Pancreatic
lipases hydrolyze retinyl esters into retinol and free fatty acids which then are absorbed
into enterocytes. Retinol is then re-esterified into retinyl esters to be packaged in
chylomicrons for delivery to other parts of the body through lymph circulation first and
then blood circulation20. Provitamin A carotenoids are enzymatically cleaved to produce
retinal which is then reduced into retinol12,21. This retinol produced is then converted to
retinyl ester so that it can be incorporated into chylomicrons22. Dietary fat is essential
for optimal absorption of VA because it acts as a facilitator for incorporation into
chylomicrons23. Foods rich in VA include liver, milk, eggs, and those rich in provitamin
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A include carrots, sweet potato and dark leafy greens10. The RDA for VA has been
established for the different life stages to prevent deficiency and toxicity24. See Table1
below for RDA of VA.

Table 1 Recommended Daily Allowance of Vitamin A based on gender and age
Life
Stage
Group
VA
(μg/day)

Children
1-3 yr

Children
4-8 yr

Males 913 yr

Males 1470 yr

Females
9-13 yr

Females
14-70 yr

300

400

600

900

600

700

Physiological VA status is regulated through a network of enzymes and proteins
which facilitate the transport, productions and catabolism of retinoids25. In this network,
retinol is reversibly converted into retinal, and retinal is irreversibly converted into RA 26.
RA has been involved in the regulation of the expression levels of the enzymes in this
system 13. However, it is important to recognize that some of the physiological functions
of retinal (such as vision) cannot be replaced through RA treatments27.
2.1.6 Mechanisms of VA and its metabolites functions
2.1.6.1 The vision cycle
Retinol metabolite, 11-cis-retinal, plays a critical role in vision. In the eyes, 11cis-retinal is bound to opsin to form rhodopsin in rods. When light enters the eyes, 11cis-retinal isomerizes to all-trans-retinal and dissociates from opsin. This results in a
nervous signal along the optic nerve to the brain. A series of enzymatic reactions
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converts all-trans-retinal back to 11-cis-retinal, which can then rebind to opsin to form
rhodopsin to complete the vision cycle10
2.1.6.2 Mechanism of Retinoic Acid (RA)-mediated transcription
RA is found in multiple forms, with all-trans RA and 9-cis RA being significant in
the body. RA regulates gene expression mainly through activating two nuclear receptor
families, RA receptors (RARα, β and γ) and retinoid X receptors (RXRα, β and γ) 12,26.
RARs and RXRs are considered part of the nuclear receptor family, which are ligandactivated transcriptional activators critical for physiological processes28,29. RARs are
activated by all-trans RA while RXRs are activated by 9-cis RA26. Activation occurs
when RAR/RXR hetero-dimers or RXR/RXR homo-dimers bind to the RA responsive
elements at the promoters of their downstream targeted genes30,31. It has been
suggested that RXR can act as a universal dimerization partner for other families of
nuclear receptors such as peroxisome proliferator activated receptors (PPARs), liver X
receptor (LXR), thyroid hormone receptor (TR), and vitamin D receptor (VDR),
indicating a complex transcriptional network which allows RA, to exert its biological
activity.32.
Chicken ovalbumin transcription factor II (COUPTF-II) nuclear receptors have
DNA-binding abilities, meaning it can activate or inhibit gene expressing depending on
the presence of ligands, corepressors or coactivators33. Deletion of COUPTF-II can
alter processes such as angiogenesis and cardiovascular development, and therefore
can be lethal33. It has been reported that COUPTF-II acts constitutively but its activity
can be modulated by the presence of RA34. RA has been reported to release COUPTF-
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II from the auto-repressed conformation, possibly affecting some of the metabolic
activities regulated by COUPTF-II34.
Hepatocyte nuclear factor 4 alpha (HNF4α) is a transcription factor responsible for
several liver specific functions such as gluconeogenesis and lipid and bile synthesis35.
It has been shown to direct 11% of genes actively transcribed in pancreatic islets36.
Compared to the liver, it is expressed in lower amounts in other tissues such as
intestine and kidneys37. The importance of the role it plays is indicated by the
development of hepatic steatosis in HNF4α deficient mouse livers35. In humans,
mutations in the HNF4α genes leads to maturity onset of type I diabetes, characterized
by pancreatic β-cell dysfunction evidenced by loss of insulin secretion in response to
glucose38. In hepatocyte, HNF4α maintains differentiation state, phenotype and also
directs energy metabolism38.
It has been observed that RA produced in intestines was found in the portal
system of the liver39, which indicates that plasma RA levels may play a role in signaling
the body’s retinoid status13. It has been demonstrated that retinoids regulate the
expression of genes involved in hepatic glucose and lipid metabolism 40,41.
2.2 Hepatic metabolism of VA
The liver plays an essential role in energy metabolism. This is in part attributed to
the regulation of expression levels of hepatic genes involved in glucose and lipid
metabolism in response to hormonal and nutritional stimuli42. Obesity and other metabolic
diseases such as diabetes have been linked to abnormal glucose and lipid metabolism in
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the liver43. It is clear that metabolic abnormalities significantly impact hepatic functions
and, thereby, contribute to morbidity.
2.2.1 Role of liver in the regulation of metabolic homeostasis
The liver is the most important site for retinoid storage in the body, accounting for
uptake of 66-75% of all dietary retinoid absorbed in the intestines44. It accounts for 7080% of all retinol binding protein (RBP) in circulation, making it the major site for RBP
synthesis and secretion22. RBP maintains circulating levels of retinol to assure
continuous delivery to target tissues under conditions of retinoid sufficiency45. The three
RARs (α, β, γ) and three RXRs (α, β, and γ) are all expressed in the liver, making it an
important target organ for retinoid actions46.
2.2.2 Role of the liver in VA homeostasis and its metabolism
The majority of dietary retinol absorbed by enterocytes is secreted into the
lymphatic system in the form of retinyl esters in chylomicrons, which contain dietary
lipids, mostly triglyceride (TG) and cholesterol22. In circulation, 66-75% of chylomicron
retinyl ester is removed by the liver while the remaining is removed by extrahepatic
tissue such as adipose tissue, skeletal muscle, heart, spleen and kidney22. Most retinyl
ester present in chylomicrons remains as the particles become chylomicron remnants in
a process involving the lipolysis of TG and recruitment of apolipoprotein E (apo E) to the
particles22. It is thought that chylomicron remnants are internalized solely by
hepatocytes47.
After chylomicron remnant retinyl esters have been up taken by hepatocytes, the
retinyl esters are hydrolyzed by retinyl ester hydrolases48. In a retinoid sufficient state,
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chylomicron remnant retinol is then transferred to hepatic stellate cells for storage 49,50.
In contrast, when dietary retinoids are insufficient more of the recently ingested retinol is
secreted into circulation bound to RBP instead of being transported into storage.
Circulating retinol bound to RBP enters and leaves the liver multiple times before
its elimination from the body. This process is called retinol recycling51. Studies in
humans show that 14.3 mg/day of retinol passes through plasma compared with a
disposal rate of 1.14 mg/day, which indicates that a large portion of retinol take up in
organs and circulating tissues is recycled back into plasma and that only a minor portion
is converted to active metabolites or degraded52. It is thought that this process of retinol
recycling provides the liver an ideal means to sample and adjust the concentration of
retinol available in plasma for peripheral tissue53. Total body retinol pool size can be
estimated with deuterated retinol dilution technique and calculation of the change in
total body retinol pool size can be achieved with the paired deuterated retinol dilution
technique54,55.
Hepatocytes play an essential role in hepatic retinoid metabolism and storage,
accounting for some retinoid storage and facilitating mobilization of retinol from the
liver22. These cells also contribute to retinoid activation to RA, to RA catabolism and to
the excretion of retinoid catabolic products22. They have relatively high concentrations
of retinol, retinyl ester, RBP, retinyl ester hydrolases, and enzymes that convert retinol
to RA22.
Mobilization of retinoids from the liver to target tissues in circulation is regulated
in a process involving RBP56. RBP has a molecular weight of 21 kDa and has a single
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binding site for one molecule of all-trans retinol22. This protein is synthesized in
hepatocytes, but its expression has also been detected in other tissues, such as kidney
and adipose tissue22. When retinol binds to RBP, the retinol-RBP complex enters the
blood stream for transport to target tissues and its concentration is maintained at 2-3
μM. This complex circulates in the blood as a 1:1 molar complex with thyroxine
hormone carrier transthyretin, making the complex less susceptible to filtration by the
kidney57,58
2.2.3 Role of VA in the metabolism of glucose in the liver
Elevation of hepatic VA content was observed in diabetic patients as early as
193759. Later, it was observed that rats fed a VA-deficient (VAD) diet had depleted
hepatic glycogen content60. This study concluded that the depletion of hepatic glycogen
was caused by the reduction of glycogenesis from trioses, rather than directly from
glucose60. The depletion in VAD rats was not due to reduced energy intake, as pair fed
rats with equal energy intake had higher hepatic glycogen content 60. When rats were
fed a diet with excess VA for 2 days, a dramatic increase in fasting hepatic glycogen
content was observed61.
It has been observed that insulin resistant humans and animals have elevated
plasma RBP 462. When mouse plasma RBP4 level was manipulated, the result was
altered insulin sensitivity and expression levels of hepatic gluconeogenic genes63. A
reduction of plasma retinol and RBP levels has been observed in patients with type I
diabetes and also in streptozotocin-induced diabetic rats64,65. Insulin sensitivity was
improved in insulin resistant ob/ob mice with administration of retinal66.
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Glucose is differentially metabolized in cells depending upon hormone and
nutrition statuses67. For it to be utilized, it must undergo phosphorylation to become
glucose 6-phosphate (G6P) through the action of hexokinases in the first step of
glycolysis. In mammals, hexokinase is referred to as glucokinase (GK)68,69. Mutations
altering the GK enzymatic activity are associated with maturity onset diabetes of the
young70. Regulation of hepatic GK activity is accomplished by its binding to GK
regulatory protein, phosphorylation by protein kinase A, and interaction with cytosolic
GK-associated phosphatase71-73. Long term regulation of GK activity is achieved
through transcription of GK gene (Gck)74. Gck is differentially regulated by an upstream
promoter in pancreatic β-cells and a downstream promoter in hepatocytes75. In the
liver, the cycle of fasting and re-feeding alters Gck expression. However the same cycle
does not alter Gck expression in pancreatic β-cells74. It has been observed that in rat
liver, Gck mRNA is induced by insulin and suppressed by glucagon76-78.
In rat hepatocytes, all-trans RA has been shown to induce Gck expression
without any additive effects on insulin mediated induction79,80. On the other hand, our
research group has reported that retinoids synergize with insulin to induce Gck
expression in rat hepatocytes40. In the liver of VAD rats, Gck activity and mRNA levels
were lower compared to VAS controls. Also, treatment with RA induced Gck mRNA in
rat hepatocytes40.
Under conditions where dietary glucose is not available, the liver will produce
glucose through gluconeogenesis. Phosphoenolpyruvate carboxykinase (PEPCK-C),
the first rate-limiting enzyme of gluconeogenesis, converts oxaloacetate into
phosphoenolpyruvate in the presence of GTP81. PEPCK-C expression and activity has
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been detected in the liver, kidney and adipose tissues, where PEPCK-C may control
gluconeogenesis, glyceroneogenesis and cataplerosis81-84. PEPCK-C is regulated by
the transcription of its gene Pck1 in different physiological conditions81-83. The hepatic
expression of Pck1 is induced by glucagon and suppressed by insulin85, meaning the
liver can produce glucose under fasting conditions. RA has been reported to stimulate
Pck1 expression, also two RA response elements (RARE) have been identified at Pck1
promoter in hepatoma cells86-88. Lipophilic extract from rat liver was found to induce
Pck1 expression and attenuate insulin-mediated suppression of its transcription89.
These lipophilic molecules were later identified as retinoids due their effects of insulininduced Gck expression40. Of the two previously identified RARE in Pck1 promoter, the
proximal one was responsible for mediating the retinoid effect in hepatocytes 86,87,90,91.
2.2.4 Role of VA in the lipid metabolism
The liver and adipose tissues, in response to dietary intake and stored energy,
regulate TG and fatty acid (FA) homeostasis in the body92,93. FAs are stored in adipose
tissue as TGs in the postprandial stage94. TG in chylomicrons and very low density
lipoprotein (VLDL) is converted to free fatty acids (FFA), monoglycerides and
diglycerides through hydrolysis by lipoprotein lipase (LPL) for entry and storage in
adipose tissues. Under fasting or starvation condition, FFAs are released from adipose
tissue though lipolysis by lipases in adipocytes95. These FFAs can then be used by
heart, liver and skeletal muscle for energy. In the liver, FFAs can be used for
ketogenesis and glycerol for gluconeogenesis. Other organs, like the brain, can then
utilize ketone bodies and glucose for energy.
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Instances of metabolic abnormalities are often associated with changes in
hepatic lipid metabolism. For instance, patients or animals with obesity and type 2
diabetes were reported to have excessive hepatic lipogenesis43. Insulin stimulates
lipogenesis and inhibits lipolysis to regulate FA and TG homeostasis96. Patients and
animals with obesity and type 2 diabetes experiencing hyperinsulinemia were
determined to have excessive hepatic production of FAs and TGs. This happens
because the liver can stimulate the expression of lipogenic genes, a process mediated
by sterol regulatory element binding protein 1c (SREBP-1c), which is an insulin-induced
transcription factor97,98. In the liver of mice, activation of liver X receptor (LXR) and RXR
induced the expression of the SREBP-1c gene (Srebp-1c)99. In Srebp-1c promoter, the
insulin responsive elements have been identified as two liver X receptor elements
(LXRE) and one sterol regulatory element (SRE)100. Retinoids induced SREBP-1c
expression and maturation, resulting in activation of the promoter activity of fatty acid
synthase gene (Fas)101,102. In rat hepatocytes, retinoids synergized with insulin to
induce expression of Srebp-1c mRNA in a dosage and time dependent manner41. The
two LXREs responsible for the insulin induced Srebp-1c expression in rat hepatocytes
were determined to be RAREs in its promoter41,100.
Patients with acne treated with isotretinoin (13-cis RA) developed
hypertriglyceridemia103. Healthy subjects given isotretinoin had elevated plasma apo CIII level. In adult hepatocytes, apo C-III was induced RXR specific agonist104. Patients
with acute promyelocytic leukemia were observed to have gained weight and elevated
levels of plasma TG and cholesterol after treatment of all-trans RA105,106. Rats
consuming a VAD diet for 3 months after weaning were reported having lower plasma
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TG and cholesterol, hepatic phospholipid contents, and hepatic synthesis of FA and
phosphatidylcholine compared to controls fed a VAS diet 107. This may be due to the
combination of VA deficiency and hypoinsulinemia, because insulin secretion is
impaired in rats fed a VAD diet108. Rats fed with all-trans RA and 13-cis RA and with 9cis RA and RAR specific agonist induced hypertriglyceridemia109,110. This is attributed
to the elevated production of VLDL in the liver and reduced uptake of TG in adipose
tissue and skeletal muscle. In vitro experiments show that rat hepatocytes treated with
RA increased the incorporation of lipid precursors into FA and TG. Reduced TG uptake
was associated with reductions of LPL activities in adipose tissue and skeletal
muscle109. Elevated plasma TG was reported for Sprague-Dawley and Zucker diabetic
fatty rats treated with a RXR specific agonist111. This was attributed to a decrease in
LPL activities in adipose tissue and skeletal muscle111. The reduction was likely
mediated by a RXR-induced protein responsible for posttranslational processing of PLP
since there were no effects of RXR activation on the mRNA level of LPL 111. It is
important to note that the role of hepatic lipogenesis in the increase of plasma TG was
not clearly defined in these studies. In obese and diabetic mice, it has been reported
that RXR sensitized insulin and reduced TG levels112. All-trans RA has been reported
to repress obesity and insulin resistance through activation of PPAR β/δ and RAR113.
Hepatic lipid metabolism was altered in mice with liver specific knockout of RXRα114. Of
note, RXRα knockout mice have elevated expression of RARβ and RARγ, which implies
the changes of RA signaling as RARβ can be up-regulated with treatment of RA115.
These observations imply the roles of VA in lipid metabolism, probably through
multiple mechanisms12. Treatment of RA may have (1) increased lipogenesis in the
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liver, (2) reduced PLP activity in skeletal muscle and adipose tissue, and/or activated
signal transduction pathways and transcription of RAR/RXR downstream targeted
genes116. The two RAREs/LXREs on Srebp-1c are mediating insulin response and
sensing nutrition VA status, meaning the retinoid and insulin signaling pathways can
converge on the same sites in Srebp-1c promoter and synergize to induce its
expression, resulting in the expression of its downstream lipogenic genes12. Because
SREBP-1c is the dominating regulator for hepatic FA biosynthesis, it has been
concluded that one of the ways that retinoids regulate lipid homeostasis is through
regulation hepatic expression of Srebp-1c 12,97. Looking at the effects of RA on insulinmediated expression of Srebp-1c and Pck1 in rat hepatocytes, it has been suggested
that RA may be one of the possible factors leading to hepatic insulin resistance 12,41,91.
2.2.5 Role of VA intake in obesity development
Previous research indicates that VA plays a key role in the development of obesity.
Patients with promyelocytic leukemia treated with all-trans RA had observed increases in
BM and plasma cholesterol105. Excess of isotretinoin (13-cis RA) given to patients for the
treatment of acne vulgaris has been shown to elevate blood TG and liver enzymes without
any change in dietary intake117,118. It has been demonstrated that Zucker fatty rats fed a
VAD diet gained significantly less weight than their VA sufficient counterparts6. It has
been observed that patients with metabolic syndrome had significantly lower levels of
plasma VA than their healthy counterparts119. Interestingly, research has demonstrated
the use of VA in the treatment of obesity.

Obese mice treated with all-trans RA

experienced weight loss and improved insulin responsiveness as a result of the all-trans
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RA inducing the expression of PPAR β/δ and RAR target genes involved in regulating
lipid homeostasis113.
The impact of VA on the mechanisms of obesity development is not well
understood. A greater understanding of the role of VA in energy metabolism and obesity
development may lead to more effective treatments for obesity and metabolic diseases.
2.3 Methods to assessing VA
2.3.1 Measuring VA in plasma
Methods have been established to quantify VA in plasma. Plasma samples first
undergo an extraction process to remove the fat soluble vitamins and carotenoids. This
extraction provides an extract suitable for reversed-phase liquid chromatography
analysis with absorbance detection120. Below is Table 2 for normal retinol plasma
levels.

Table 2 Reference Intervals for normal retinol plasma levels in humans based on age
Life Stage
0-1 month
2 months-12 years
13-17 years
18 years and older

Reference Interval
0.18-0.50 mg/L
0.20-0.50 mg/L
0.26-0.70 mg/L
0.30-1.20 mg/L
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2.3.2. Measuring VA in the tissues
For establishing tissue concentration of VA, there is far less data than for plasma
concentration10. Research indicates greater concentrations in tissue than plasma in
rats10. For instance, it has been reported that normal rats have tissue concentrations
ranging 40-580 pmol/g (kidney, liver, lung and pancreas) compared to a plasma
concentration of 8-16 pmol/ L10.
2.4 Role of western diet in the development of metabolic diseases
2.4.1 High-Fat Diet (HFD)
2.4.1.1 The definition of HFD and current status in population
With one third of Americans being considered obese, obesity has reached
epidemic level in the United States1. This is a concern of public health as obesity leads
to the development of various metabolic diseases2, which result in higher mortality rates
and higher costs in health care.
One of the dietary styles contributing to the obesity epidemic is the Western Diet
(High-fat content), which is characterized by a high intake of red and processed meats,
eggs, refined grains and sugars, and energy derived from fat, mainly saturated fatty
acids, which can be as high as 35% of energy intake121,122. The Dietary Guidelines
published by the USDA recommends that dietary fat provide 20-35% of energy,
emphasizing consumption of n-3 polyunsaturated fatty acids (PUFA) while limiting the
intake of saturated and trans fatty acids123. It has been reported that the fat intake of an
average adult is 33% of energy intake124. However, it is important to note that adults
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may consume more total kcal than recommended so fat intake would still be higher than
recommended.
2.4.1.2 Studies using HFD
The consequences of consuming a HFD have been documented in human and
animal subjects. The HFD pattern has been positively related to BMI and has been
linked to increased risk for type 2 diabetes, coronary heart disease and colon cancer 122.
The intake of a HFD not only increases risk for these diseases, but also reduces
functions of the immune system121. Additionally, high fat diet consumption may induce
inflammatory pathways in individuals121.
The detrimental effects of HFD consumption have been studied in animals
extensively. For example, mice fed a HFD (45% energy from fat) for 12 weeks
developed obesity, hyperinsulinemia, hyperglycemia, and hyperleptinemia125. High fat
feeding alters mechanisms for digestion and absorption. Mice fed a HFD demonstrated
significant differences in transcript levels of pancreatic enzymes compared to
controls125. Sprague Dawley rats placed on a HFD for 10 weeks demonstrated greater
oxidative stress (measured by serum levels of urinary-8-epi-prostaglndin-F2α and
glutathione peroxidase) than controls fed a normal chow diet126.
Preventing the intake or reducing the absorption of dietary fat has been shown to
be beneficial to control the development of metabolic diseases. Reducing fat absorption
may alter the outcomes of HFD feeding. Patients with obesity receiving120 mg three
times/day of Orlistat(a drug that acts as a lipase inhibitor, preventing the digestion and
then, absorption of dietary fat) for one year had significant reduction of body weight in
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association with decrease in levels of vitamin E (VE) and β-carotene, but not VA and
vitamin D (VD), compared with those receiving placebo, indicating the essential role of
fat absorption in the maintenance fat-soluble vitamin homeostasis127. On the other
hand, a 12-week treatment of Orlistat (120 mg three times daily) significantly reduced
the plasma levels of VA and VE in addition to the reductions of body weight and fat
mass in patients with obesity128.
2.4.2 Lipophilic vitamins in HFD conditions
Based on their solubility in aqueous solution, vitamins are classified as either
hydrophilic or lipophilic. Fat soluble or lipophilic vitamins are VA, VD, VE, and vitamin K
(VK). They can be stored in the body. Historically, those lipophilic vitamins were
identified due to the symptoms caused by their deficiencies in animal and human
studies such as growth cessation in animals for VA and rickets for VD.
Upon intake, lipophilic vitamins are digested, absorbed and embedded with
dietary fat, and transported with chylomicrons through circulation. The major component
of dietary fat, triacylglycerol in chylomicrons is delivered and stored into peripheral
tissues due to the action of lipoprotein lipase in the body. It seems to be possible that
the amount of dietary fats and their compositions may affect functions, availability and
metabolism of lipophilic vitamins, which in turn may affect body health. Here, we try to
summarize the current understanding and progress of human and animal research work
regarding the effects of HFD intake on functions and availability of lipophilic vitamins.
VD is incorporated into micelles and enters enterocytes through passive
diffusion. After absorption, VD is then packaged in chylomicrons in enterocytes and
delivered throughout the body through lymph circulation. VD synthesized in the skin is
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transported through the body by VD-binding protein (DBP). Once VD reaches the liver,
either through chylomicron remnants removal or DBP, it is hydroxylated to 25Hydroxycholcalciferol (25-OH-D3)10,129.
Within the small intestine, dietary VE is incorporated into micelles. The pancreas
secretes esterases that act on VE esters to yield free VE which then enters enterocytes
through passive diffusion. In enterocytes, VE is packaged in chylomicrons and
delivered to the rest of the body through lymph circulation 130.
In intestine, dietary VK is incorporated into mixed micelles comprising dietary
lipids, bile salts, and products of pancreatic lipases.131 Dietary VK is then absorbed
into enterocytes through active transport. VK is then incorporated into chylomicrons
which will enter lymph circulation for delivery to other parts of the body131.
Chylomicrons travel through circulation, are embedded into peripheral tissue and
deposit cargo due to the action of lipoprotein lipase. Chylomicron remnants are
eventually taken by the liver where VK is incorporated into VLDL which re-enters
circulation and can be up taken by osteoblasts.131
Dietary intervention in humans can cause the change of plasma levels of
lipophilic vitamins. In participants of a randomized, double-blind, placebo-controlled
clinical trial, daily intake of 8.8 grams (g) of plant stanol esters for 10 weeks did not
change serum levels of VA, VD and γ-tocopherol, but reduced the levels of total and
LDL cholesterol, carotenes and α-tocopherol132. A 2.6 g/day dose also significantly
reduce total cholesterol (LDL), total TG, and carotenes levels, but not VA and VE133. In
a moderately hypercholesterolemic population, sitostanol ester (3 g/day) for a year
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significantly reduced the plasma levels of α-tocopherol and carotenes in association
with the reduction of cholesterol, but not VA and VD levels134. On the other hand, short
term (2-7 days) intake of HFD in human, did not affect the plasma levels of cholesterol,
TG, carotenes and VE135.
The effects of VA in HFD feeding have been explored in animal models.
Supplementation of additional VA in HFD caused further increase of plasma TG levels
and expression levels of genes for adipocyte differentiation in rats already fed a HFD 136.
On the other hand, in male mice, a supplementation of VA (20IU /g of diet) in a HFD
increased plasma levels of IL-18 and macrophage inflammatory protein-1 (MIP-1γ),
which occurred in a RALDH1 (Aladh1 for gene)-dependent manner137.
Adverse effects of excessive intake of VA on human and animals have been
nicely summarized138. Male Sprague-Dawley rats fed on a high-fat diet supplemented
with large doses of chitosan have reduction of liver VA and VE, but not VK, levels,
demonstrating the effects of dietary components on the fat soluble vitamin statuses in
the body139. It has been shown that dietary fat and fiber contents affect the VA storage
in the liver and conversion of β-carotene into retinol in Mongolian Gerbils140. VA
supplementation down-regulates leptin mRNA in adipose tissue in mice and RA
stimulates UCP3 mRNA in muscle141.
For VD to become activated, parathyroid hormone stimulates the kidneys to
release the enzyme 1α-hydroxylase, which converts 25-OH-D3 to 1α,25Dihydroxycholecalciferol (1α,25-(OH)2D3)142. DBP binds to 1α,25-(OH)2D3 so that it is
carried to target tissues throughout the body where it can be a ligand for VD receptor
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(VDR). 1α,25-(OH)2D3 enters cells and binds to VDR causing VDR to form a
heterodimer with RXR which acts as a transcription factor to regulate gene
expression10.
There is an association of reduced serum 25-hydroxyvitamin D (25D)
concentrations with the development of human obesity143. However, the effect of VD
supplementation on body weight reduction seemed to be uncertain 143. In children (6-10
year-old), a slight lower value of serum 25D (drop from 26 ng/ml of nonobese to 23
ng/ml of obese) was also associated with obesity144. A recent randomized controlled
study using seven doses of VD (400–4800 IU/d) in both lean and obese female subjects
showed that the rise of blood VD levels is inversely related to the body fat mass, and
the normalization of blood VD levels is not associated with reduction of body weight in
obese subjects145. At this time there appears to be no published research investigating
the effect of a HFD and VD intake and its plasma level in participants.
Both male and female VD receptor knockout mice have a lean phenotype and
demonstrate resistance to HFD-induced obesity regardless whether they are in the
C57BL/6J or CD1 outbred background146-148. On the other hand, transgenic expression
of human VDR driven by aP2 promoter in adipose tissue resulted in gains of BM and
body fat mass in mice149. This phenotype is associated with the elevation of only plasma
cholesterol level and changes of expression levels of genes for fuel metabolism in fat
tissues and the skeletal muscle149.
When SD rats were fed a diet containing low fat (LFD, 10% energy from fat) or
HFD (45% energy from fat) with normal VD or depleted VD (VDD), rats in HFD-VDD
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group had higher nonalcoholic fatty liver disease (NAFLD) activity Score (NAS) than
rats in HFD-VD group. On the other hand, rats in LFD groups are protected to the
development of NAFLD150. The elevation of NAS in rats of HFD-VDD group is
associated with change of the expression of genes for hepatic inflammatory and
oxidative stress, suggesting the protective role of VD to the development of NAFLD 150.
However, feeding HFD (40% energy from fat) in rats for 12 weeks per se did not change
serum 1,25-dihydroxyvitamin D(3) level, whereas supplementation of lactose (10% of
the diet weight) significantly reduce VD level and HFD-induced BM gain151.
VE is a collective term for tocopherols and tocotrienols. These molecules differ
in their side chains; tocopherols have a phytol side chain while tocotrienols have an
unsaturated side chain. Only four tocopherols and four tocotrienols meet human VE
requirements10, but in the human body α-tocopherol is the most effective152.
VE is of significant interest because it is a lipid soluble antioxidant. It serves as
a radical scavenger that protects polyunsaturated fatty acids in membranes and
lipoproteins against lipid oxidation. Alpha tocopherol scavenges a radical through
donating a hydrogen with the resulting alpha tocopherol radical reacting with ascorbate
to return to its reduced state.152
It has been observed that overweight subjects (BMI ˃ 27) taking an antioxidant
supplement (1g vitamin C/800 IU VE) with a high-fat low-carbohydrate diet (63.6 ± 1.6%
calories as fat) for 8 days had a trend of lower C-reactive protein (30% reduction
compared to baseline). One the other hand, subjects in the placebo group had a trend
for higher levels of CRP (50% increase compared to baseline153.
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Several studies have been done in animals to determine the effects of VE in
HFD condition. Feeding of VE did not affect the plasma lipid levels in lean or obese
mice fed a HFD154. The HFD-induced activation of JNK in rat skeletal muscle was
attenuated by including antioxidants including vitamin C and VE in Wistar rats155. Male
C57BL/6J mice fed a HFD (70% energy from fat) with elevated VE content had
elevation of α-tocopherol in the liver and adipose tissues, which might be protective
against lipid peroxidation156. Supplementation of VE (α-tocopherol) or VD (D3) in HFD
significantly reduced the plasma level of IL-6, but not IL-10, in HFD-fed male Swiss
mice157. Tocotrienol supplementation also reduced damages of feeding highcarbohydrate and high-fat diet to the heart and liver in Wistar rats158. A 6-week VE (αtocopherol) treatment at a dose of 100 mg/kg daily via oral gavages significantly
reduced the memory impairment induced by High-fat and High-carbohydrate diet in rats,
probably through reduction of oxidative stress in the hippocampus159. Specific increase
of VE content in mitochondria using a mitochondria-targeted VE derivative, MitoVit E
(conjugated with triphenylphosphonium cations) has been shown to reduce hepatic
oxidative stress and inhibit fat deposition in mice160.
When mice were fed a HFD supplemented with α-tocopherol (VE, 0.9 g/kg of
diet) and 1,25(OH)2 vitamin D3 (0.05 mg/Kg of diet) for 8 weeks, they had lower plasma
levels of IL-6, indicating reduction of inflammatory response157. It was suggested that
these two vitamins inhibit IL-6 production from adipocytes157. HFD induced obese SD
rats supplemented with 350mg/kg diet of DL-α-tocopherol acetate exhibited significantly
less BM and fat weight126.
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VK is essential in blood clotting and bone formation. Quinone oxidoreductases
reduce VK to vitamin K hydroquinone. Vitamin K hydroquinone serves as a cofactor for
vitamin K gamma-carboxylase, which catalyzes the carboxylation of certain glutamic
acid residues, resulting in their activation in blood clotting and bone formation. A
reduced VK molecule is converted to vitamin K epoxide and then converted back to VK
by vitamin K epoxide reductase161. This reduction and reoxidation of VK coupled with
glutamic acid carboxylation is referred to as the VK cycle10. Because VK is recycled in
the body, human deficiency of VK is rare161.
Rats fed a HFD diet (45% more energy from fat) rich in corn oil had lower plasma
VK level than those fed a low fat diet even more VK was present in the HFD, indicating
the HFD feeding on the plasma level of fat-soluble vitamins162. Additionally, the liver VK
levels was reduced in rats fed a low-fat diet with fish oil, but not that fed a HFD (already
lowered ) with fish oil163.
2.5 Investigating weight loss in participants who are overweight and obese
2.5.1 Current recommendations for obesity treatment
For the treatment of obesity in adults, comprehensive lifestyle interventions have
been recommended164. This consists of diet and physical activity goals, as well as
behavioral therapy. Dietary goals to achieve weight loss for adults who are overweight
and obese should be individualized and include a 500 to 750 Calories/day deficit164.
Physical activity goals aim to gradually increase the amount of physical activity to at
least 30 minutes of moderate to vigorous intensity physical activity on as many days as
possible. Behavior therapy assists with behavior modification strategies, which are
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implemented to change participants’ dietary intake and physical activity.
Recommended behavior modification strategies to assist in changing diet and physical
activity include stress management, self-monitoring, problem solving, stimulus control,
cognitive restructuring, time management and social support164.
2.6.2 Weight loss interventions in adults
Typically weight loss interventions in adults include dietary changes, physical
activity goals, and behavior modification. A low-Calorie diet is currently recommended
to aid in weight loss164. The Dietary Guidelines, provided by the USDA, give standard
recommendations for dietary changes. For adults, it is recommended that dietary intake
consists of 45-65% carbohydrates, 10-35% protein, and 20-35% fat123. Many
investigations on weight loss will limit participant dietary fat consumption to 30% or less
of calories from fat165-167. Current weight loss interventions in adults do not included
prescriptions for VA intake so it is not well understood how VA intake may be related to
weight loss.
2.6 Conclusion
Obesity has reached epidemic levels with one third of this country’s population
considered to be obese1. This condition increases the risk of development of several
metabolic diseases2, resulting in higher mortality rates and costs in health care3. This
problem is multifactorial, with energy imbalance, genetics and environmental factors
playing a role4-5.
Previous research indicates that VA may also play a role in the development of
obesity6. It is clear that VA plays a role in glucose and lipid metabolism in both animals
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and humans59-65, 92-116. While VA intake has been shown to impact obesity
development, research investigating VA and obesity development in adults is limited,
with most of the research looking at the effects of excessive VA intake105, 117-118.
One of the contributions to the obesity epidemic in this country is the Western
dietary pattern, characterized by a HFD. Consuming a HFD has been linked to
increases in BM and risk of metabolic diseases121-125. The current research on lipophilic
vitamin in HFD has focused mostly on their protective roles in HFD feeding
conditions129-153.
Current recommendations for treatment of obesity in adults include dietary
changes, physical activity goals and behavior therapy164. A low-Calorie diet is currently
recommended to aid in weight loss, with many weight loss interventions limiting fat
intake to 30% or less of calories consumed164-167. Currently, weight loss investigations
in adults do not involve interventions for VA intake. It is not clear how VA intake may be
related to weight loss in adults.
2.6.1 Specific aims
This thesis includes two parts. The project seeks to answer the following questions:
Does the presence of VA in the diet have an effect on weight gain while a high-fat,
obesogenic diet is consumed? Is the presence of VA in the diet related to successful
weight loss when a hypocaloric, low-fat diet is consumed? This thesis project incorporated
two different models to investigate the impact of VA in obesity. The first is an animal
model, where animals were fed a high fat diet with the goal of weight gain during dietary
treatment. The second model looked at adults, where participants’ fat and energy intake
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were restricted with the goal of achieving weight loss. The two experiments examined
the following aims:
1. Investigate the contributions of VA intake on obesity development in rats
fed a high-fat diet (HFD).
2. Investigate the effects of VA intake on body weight alterations in
participants during a hypocaloric, low-fat dietary intervention.
For this thesis project we hypothesized that VA intake will have an effect on
obesity development when an obesogenic HFD is consumed. We also hypothesized
that achievement of 10% weight loss would be related to a lower dietary VA intake when
weight loss was due to consumption of a hypocaloric, low-fat diet.
It is important to note the use of different models for the experiments in this
thesis. Because one model investigated weight gain and the other investigated weight
loss, two different mechanisms (weight loss and weight gain), as well as two different
diets, high-fat and low-fat, were examined.
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Chapter III
Effects of Vitamin A in the Body Mass Gain in Sprague-Dawley Rats
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3.1 Introduction
Obesity has become epidemic in this country with one third of Americans
considered to be obese1. This epidemic predicts the increased incidence of various
metabolic diseases2, resulting in higher mortality rates and higher costs in health care 3.
The increases in mortality rates and costs of health care have become an urgent
problem, so finding solutions must become priority.
One of the dietary styles contributing to the obesity problem is the western diet
(High-fat content), which is characterized by a high intake of red and processed meats,
eggs, refined grains and sugars, and energy derived from fat, mainly saturated fatty
acids, which can be as high as 35% of energy intake121,122. The Dietary Guidelines has
recommended that dietary fat provide 20-35% of energy124. It has been reported that
the fat intake of an average adult is 33% of energy intake124, but it is important to
recognize that adults may consume more total kcal than recommended so fat intake
would still be higher than recommended.
Lipophilic vitamins share the same routes of digestion and absorption as lipids.
Previous research has established the impact of lipid digestion and absorption on
lipophilic vitamins. Obese patients receiving120 mg of Orlistat three times/day (a drug
that acts as a lipase inhibitor, preventing the digestion and then, absorption of dietary
fat) for one year had significant reduction of body mass (BM) in association with
decrease in levels of vitamin E (VE) and β-carotene, but not vitamin A (VA) and VD
(VD), compared with those receiving placebo, indicating the essential role of fat
absorption in the maintenance fat-soluble vitamin homeostasis127. Additionally, a 12week treatment of Orlistat (120 mg three times daily) was shown to significantly reduce
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the plasma levels of VA and VE in addition to the reductions of body weight and fat
mass in patients with obesity128. Because VA shares the same routes of digestion and
absorption as lipids, we hypothesize that VA intake will have an effect on obesity
development in subjects consuming an obesogenic high-fat diet (HFD).
Here, we compared the growth current and plasma parameters of rats fed a HFD
with sufficient amount of VA (HF-VAS) and a HFD without VA (HF-VAD) diet for eight
weeks.
3.2 Materials and methods
3.2.1 Animals and diets
Male Sprague Dawley (SD) rats were bred at the University of Tennessee at
Knoxville (a breeding colony since 2012). Our previous investigations of VA in energy
metabolism have used Zucker fatty rats as a model for obesity6,91 Zucker fatty rats
develop obesity because they express a missense mutation in the extracellular domain
of all leptin receptor isoforms168. For this investigation SD rats were used so that the
findings can be applied to other strains of rats (protocol# 1582).
Animals were kept in the Animal Facility for the Nutrition Department at the
University of Tennessee. Facility temperatures are maintained at 70-73 ºF, the humidity
ranges from 45-65% and has a light and dark cycle in 12 hour increments (with the lights
on from 6:00 a.m.-6:00 p.m.) Two to three rats were placed in a single cage and fed ad
libitum. Cages were cleaned twice a week and given a fresh enrichment (either a piece
of PVC pipe or a paper cone). They were housed in colony cages and fed either a high
fat diet that is HF-VAD (0 IU/g VA) or HF-VAS (22.1 IU/g VA) after weaning (three weeks
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of age) for a total of eight weeks. This period of eight weeks will be sufficient to induce
VA deficiency.8 The HF-VAS diet had 60% energy from fat. Average fat intake is close
to 30% total calories from fat, so the fat content in the experiment is double the average
fat intake. The HF-VAD diet was identical to the HF-VAS differing only in VA content.
Diets for this experiment will be ordered from Harlan.
BM and food intake (in grams) were recorded weekly6. BM was measured for each
rat to the nearest 0.01 gram with a calibrated scale. Food intake was measured by
weighing the amount of feed given at the start for the week then subtracting the amount
remaining at the end of the week and dividing the total by the number of rats that
consumed the diet to get each rat’s weekly intake. All procedures were approved by the
Institutional Animal Care and Use Committee at the University of Tennessee at Knoxville
(865-946-2574).
3.2.2 Collection of plasma and tissue samples
At the end of eight weeks of dietary treatment, plasma glucose was measured
with an assay kit (Procedure No. 1070) from STANBIO Laboratory (Boerne, Texas).
Rats were euthanized with CO2 and spinal cord dislocation in accordance with
regulations. Hepatic blood was collected and centrifuged at 3,000 rpm for 30 minutes to
collect plasma. Liver, white adipose, brown adipose were collected, weighed, snapped
frozen in liquid nitrogen and stored at -80˚C.
Before euthanization, glucose level of the tail tip whole blood was measured
using a glucose meter (Roche; Tucson, AZ). Tail blood (less than 10 ul) was collected
with 25 G needle. Once rats were euthanized, hepatic blood was collected from the
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vena cava, then the liver and white adipose were collected. Brown adipose was
collected from the back of the neck. Tissues were weighed on a calibrated scale to the
nearest 0.01 gram, wrapped in aluminum foil and frozen with liquid nitrogen. Plasma
and tissue samples were then stored at -80 º C before used.
Measuring glucose from hepatic blood was accomplished with the technique
described Trinder et al169. With this method, glucose is oxidized in the presence of
glucose oxidase. The hydrogen peroxide formed reacts, under influence of peroxidase
with phenol and 4-aminoantipyrine to form a red-violet quinine complex. The intensity
of the color is proportional to glucose concentration. Absorbance at 500 nm wavelength
is then measured with a spectrometer from Glomax (Madison, WI). The glucose
reagent contains phosphate buffer (200 mmol/L), phenol (4 mmol/L), 4-Aminoantipyrine
(0.2 mmol/L), glucose oxidase (˃15 KU/L) and peroxidase (˃1.2 KU/L).
For glucose measurement, glucose reagent stored at 2-8 º C, was removed from
4°C refrigerator and allowed to warm at room temperature for 30 minutes. Plasma
samples were removed from storage and placed on ice to thaw. For each standard,
sample and control, 1.0 mL reagent was added to cuvettes and warmed to 37ºC for 5
minutes. 10μL of each sample was added to its respective cuvette, mixed gently and
returned to 37ºC incubation. After five minutes of incubation, absorbance of samples
was measured. Glucose for each sample was calculated as
mg

Glucose ( dL ) =

Absorbance of unknown
Absorbance of standard

mg

*100Glucose ( dL ) =

Absorbance of unknown
Absorbance of standard

*100
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3.2.3 Statistics
Data was analyzed using independent-samples t test, as seen in previous
research6,40,149. Student t test was conducted to compare means of food intake, liver
mass, white adipose mass, brown adipose mass, and blood glucose. Differences were
considered statistically significant at p < 0.05.
For comparing BM over time, a Bonferroni correction was used to calculate the pvalue to determine if differences were considered statistically significant. BM for the
groups was measured at baseline and then once a week for the eight week dietary
treatment. The Bonferroni correction was calculated as 0.05 divided by 9 (total time
points BM was measured). Differences in BM over time were considered statistically
significant at p < 0.0056.
3.3 Results
Rate of BM gain was significantly less in rats fed HF-VAD starting at 7 weeks
To determine the effects of VA status on the gain of BM in SD rats, they were fed
a HF- VAS or a HF-VAD diet for 8 weeks after weaning. Animals were weighed once a
week for eight weeks. There was no significant difference in starting BM between HFVAS and HF-VAD groups. As shown in Figure 1, rats fed a HF-VAD diet grew at a
similar rate as those fed a HF-VAS diet did for the first 6 weeks. Starting at week
seven, there was an observed significant difference in BM gain between the HF-VAS
and HF-VAD groups, with the HF-VAD group weighing less. This trend continued for
the remainder of the diet treatment, with increasing significance. This trend can be
seen in Figure 1. The BM of both groups continued to rise throughout the 8 week study
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period. Of note, without the Bonferroni correction, significant difference in BM was
detected at week 6 of dietary treatment.
Figure 2 shows the weekly food intake of the rats fed the perspective diet. Of note, the
total food intake for both groups was not significantly different. These results show that
SD rats fed a HF-VAD were able to gain BM for 8 weeks. It was not until week seven
that the rate of BM gain began to differ significantly between HF-VAD and HF-VAS.
This suggests that the VA storage of SD rats at weaning is sufficient to support the BM
gain for 6 weeks without any significant reduction in the rate of BM gain. These results
demonstrate that the deficiency of dietary VA slowed down the rapid BM gain of SD rats
fed HFD.
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Figure 1 Comparison of Body Mass gain over 8 weeks of Sprague-Dawley rats
receiving a high-fat diet and vitamin A sufficient diet (HF-VAS) and Sprague Dawley rats
receiving a high-fat and vitamin A deficient diet (HF-VAD)(* for comparing the two
dietary groups, all p < 0.0056). VAD- Vitamin A Deficient; VAS- Vitamin A Sufficient
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Figure 2 Total amount of diet consumed over 8 weeks of Sprague Dawley rats fed a
high-fat and vitamin A sufficient diet (HF-VAS) and Sprague Dawley rats fed a high-fat
and vitamin A deficient diet (HF-VAD)
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VA deficiency resulted in morphological and metabolic changes in SD rats
The effects of VA deficiency on SD rat metabolism were analyzed after they had
been fed a HF-VAD or a HF-VAS for 8 weeks. As seen in Table 1, the initial BM of the
SD rats (3 weeks after birth as weaning) fed a HF-VAD diet was similar to the HF-VAS
groups. After 8 weeks of diet treatment, HF-VAD group had significantly lower BM
(267.5 ± 32.7 g vs. 386.4 ± 37.7 g). This demonstrates the reduced somatic growth and
VA deficiency as shown previously8. At the end of the eight weeks, liver, white adipose
and brown adipose were collected and weighed. There was an observed significant
difference between the groups for liver and white adipose weight (all p<0.05), with the
HF-VAD group having less mass for liver and white adipose. While there was not a
significant difference for brown adipose mass (p = 0.070). All of these results
demonstrate the impact of VA deficiency in SD rats after 8 weeks on the HF-VAD diet.
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Table 3 Comparison of measures for Sprague Dawley rats receiving a high-fat vitamin
A sufficient (HF-VAS) diet and Sprague Dawley rats receiving high-fat vitamin A
deficient (HF-VAD) diet
Diet

HF-VAD(mean±SD) (n)

HF-VAS(mean±SD)(n)

Start day BM (g)

45.5 ± 6.5 (9)

44.7 ± 3.43 (6)

End day BM (g)

267.5 ± 32.7 (9)

386.4 ± 37.7 (6)*

Liver mass (g)

9.01 ± 1.42 (9)

14.88 ± 1.91 (5)*

Liver/BM ratio

1:29.7 (9)

1:25.9 (5)

White adipose mass (g)

2.16 ± 0.91 (7)

3.8 ± 1.25 (6)*

White adipose/BM ratio

1:123.87 (7)

1:101.68 (6)

Brown adipose mass (g)

0.31 ± 0.099 (7)

0.45 ± 0.13 (6)

Plasma glucose (mg/dl)

479.8 ± 179.2 (5)

434.5 ± 41.9 (4)

Plasma cholesterol (mg/dl)

530.6 ± 12.3 (5)

537.5 ± 17.5 (4)

Plasma triglyceride (mg/dl)

60.4 ± 30.8 (5)

70.0 ± 16.3 (4)

Note: BM-body mass, HF-VAD-high fat vitamin A deficient, HF-VAS- high fat vitamin A
sufficient
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3.4. Discussion
The growth curves of SD rats fed a HF-VAD or a HF-VAS diet demonstrate that
VA content in the diet significantly impacted obesity development (BM gain) while
consuming an obesogenic diet. Lack of VA in the diet began to reduce the rate of BM
gain starting at week 7 for rats consuming the HF-VAD diet. The rats fed a HF-VAD diet
still gained BM at a slower rate for the remaining week of dietary treatment. This
difference could not be explained by any change in total energy intake because both
HF-VAD and HF-VAS groups consumed similar total calories for the 8 week dietary
treatment. Our previous experiments have shown that Zucker Lean and Zucker Fatty
rats consuming a normal chow diet deficient in VA would reach a peak BM and then
would start to lose BM with continued dietary treatment6 in contrast to the current
experiment where the VAD group still gained BM throughout the 8 weeks of dietary
treatment. A possible explanation for this difference is the high caloric content of the
HF-VAD. Another reason for the difference could be that VA storage in SD rats differs
from VA storage in Zucker Lean and Zucker Fatty rats.
The net white fat mass was significantly lower in HF-VAD subjects than HF-VAS
subjects. It has been demonstrated that rats fed a VAD diet had a loss of carcass fat,
along with a reduction of BM170. These findings indicate that VA status plays a role in
adiposity.
The net liver mass was significantly lower in HF-VAD subjects than HF-VAS
subjects. On the other hand, there was no significant difference found in liver/BM ratio
between SD rats fed a HF-VAD diet and SD rats fed a HF-VAS diet. A possible
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contribution to the lower liver mass observed in the HF-VAD rats compared to the HFVAS rats is depleted hepatic glycogen content. It has been observed that rats fed a VAdeficient diet had depleted hepatic glycogen content60. In that study it was determined
that the depletion of hepatic glycogen was caused by the reduction of glycogenesis from
trioses, rather than directly from glucose60. It was shown that the depletion in VAD rats
was not due to reduced energy intake, as pairfed rats with equal energy intake had
higher hepatic glycogen content60. This is comparable to the findings in the current
study, as shown in Figure 2, SD rats fed a HF-VAD diet had equal total energy intake
for the 8 week diet treatment as the SD rats receiving a HF-VAS diet.
No significant difference was detected in the plasma glucose levels between the
HF-VAD and HF-VAS groups. Previous research from our lab showed a significant
difference in the plasma glucose of Zucker Fatty rats fed a normal chow VAD compared
to their VAS counterparts6. Differences in results could possibly be attributed to the use
of a different strain of rat. SD rats may have greater storage of VA at weaning than
Zucker Fatty rats and therefore may not have the same impact from a VAD diet on
glucose metabolism. Alternatively, this difference may be caused by the presence of
high fat content in the diets, which probably provide enough fatty acid for the muscle to
use. This may spare glucose and prevent the drop of glucose in HF-VAD rats.
Additionally, no significant difference was found in the plasma cholesterol and
plasma triglycerides between the HF-VAD and HF-VAS groups. Previous research from
our lab showed a significant difference in the plasma triglycerides of Zucker Fatty rats
fed a normal chow VAD compared to their VAS counterparts6. An explanation for this
difference could be the high fat content of the diet treatment used in this experiment.
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3.5 Conclusion
The current research on lipophilic vitamins in HFD has focused on their
protective roles in HFD feeding conditions. How HFD affects homeostasis of lipophilic
vitamins remains to be an open question. Our current findings support the assertion that
VA status plays a key role in adiposity development in HFD conditions
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Chapter IV
Comparison of Dietary Vitamin A Consumption in Participants with 10% Body
Weight Loss and Those without 10% Weight Loss in a Randomized Clinical Trial
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4.1 Introduction
Obesity continues to be a serious national problem with one third of the population
considered to be obese1. This condition increases the risk of development of various
metabolic diseases2 such as diabetes and hyperlipidemia, resulting in higher mortality
rates and higher costs in health care3. Additionally, obesity has been linked to decreased
productivity in the workplace, which can indirectly increase healthcare costs 3.

The

increases in mortality rates and costs of health care have become an urgent problem,
which finding solutions must become priority.
The problem of obesity is thought to be caused by positive energy balance,
meaning that energy intake is greater than energy output4. While over nutrition seems to
be an obvious cause of obesity development, the role of individual micronutrients has not
been revealed. Previous research indicates that vitamin A (VA) may play a role in the
development of obesity6.

It has be demonstrated that patients with promyelocytic

leukemia treated with all-trans retinoic acid (RA) experienced increases in body mass
(BM) and plasma cholesterol105. While this demonstrates the effects of excess VA on BM
gain in humans, it is currently not understood how dietary VA plays a role in weight loss,
and its role when a hypocaloric, low-fat diet is consumed.
This project aims to investigate the effects of VA intake on BM alterations in
participants during dietary interventions. This will be achieved by comparing dietary VA
intake between participants who successfully lost 10% weight and those who did not at 6
months in a lifestyle intervention. Based on previous research, we hypothesized that
participants who achieved 10% weight loss will have consumed significantly less dietary
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VA than those who did not achieve 10% weight loss while consuming a hypocaloric, lowfat diet.
4.2 Methods
4.2.1 Study design
A secondary data analysis as conducted using data collected from a previous
published lifestyle intervention trial which examined a reduced variety dietary
prescription165. In the original study, 202 participants who were overweight and obese
were randomly assigned 1 of 2 conditions: Limited Variety (LV) or Lifestyle. Both of the
treatment conditions were given a standard low-calorie, low-fat diet prescription (1200
kcal/day for participants weighing less than 200 lbs at baseline and 1500 kcal/day for
participants weighing greater than 200 lbs at baseline, with fat being restricted to 30% of
energy intake), a physical activity prescription consisting of 200 minutes of moderateintensity physical activity per week and walking 10,000 steps per day, and a cognitive
behavioral intervention to aide in dietary and physical activity behavior changes165. The
LV was also given a limited variety prescription, designed to decrease the number of
non-nutrient-dense, energy-dense foods (NND-EDF) (for example ice cream, cookies,
chips) consumed to only 2 selected by the participants165. The NND-EDFs also
included modified versions such as reduced sugar and sugar free ice cream.
Participants in the Lifestyle group did not receive the limited variety prescription.
Participants participated in the intervention for 18 months, which provided 48, 60
minute group sessions. These sessions, modeled after lessons used in the Diabetes
Prevention Program, covered lessons on behavioral and cognitive skills to aide with
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dietary and physical activity behavior changes. During the first 6 months, which was
considered the weight loss phase, participants had weekly sessions. Months 7-18
were considered the maintenance phase so the participants had two sessions a
month165. Measures were taken at baseline, 6, 12, and 18 months.
At the end of the study it was found that the LV group consumed less variety of
NND-EDFs and less overall energy intake daily from these foods than the Lifestyle
group at 6, 12, and 18 months165. While the LV group consumed less total energy than
the Lifestyle group at 6 months, there were no significant differences between the
groups in energy intake at 12 and 18 months165. Weight loss did not differ significantly
between groups and at 18 months both groups lost approximately 9% of body weight 165.
The current study was a secondary data analysis. The time point examined was
month 6. For analysis, the participants were divided into two groups, successful weight
loss at 6 months (loss of 10% or more of body weight), and unsuccessful weight loss at
6 months (loss of less than 10% of body weight). Weight loss of 5-10% in overweight
and obese subjects has been shown to improve risk factors for diseases related
obesity171. The dependent variables that were investigated are VA intake. Variables
for VA included Total Vitamin A Activity International Units, Beta Carotene provitamin A
carotenoid, Total Vitamin A Activity Retinol Equivalents, Beta Crytoxanthin provitamin A
Carotenoid, Alpha Carotene provitamin A carotenoid.
4.2.2 Participants
In the initial study, participants were recruited from Providence, RI and Knoxville,
TN. Eligibility criteria included aged 21-65 years, a BMI between 27 and 45 kg/m2, and
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the ability to walk 2 blocks165. Participants were excluded if they reported a heart
condition, chest pain, or loss of consciousness; were taking weight loss medications or
participating in another weight loss intervention; had undergone bariatric surgery; were
pregnant or lactating, or less than 6 months post-partum or planning to become
pregnant during the study; were allergic to foods being used in the taste-test measures
conducted during the study; or were consuming less than 5 different types of NNDEDFs165. For the current secondary data analysis, only participants with complete
dietary data and weight measurements at baseline and 6 months were included in the
analyses.
4.2.3 Measures
Measures were collected by trained research staff blinded to the randomization
assignment at baseline and 6 months in a research setting. Demographic measures,
such age and race, were collected through a self-report survey at baseline165. Of note,
all of the measures collected for participants were not collected at the same time of the
year. The study collected measures from 6 different cohorts over time.
Anthropometrics
Participant height was measured at baseline and weight measures were taken at
baseline and 6 months to calculated BMI. Height measurements were recorded to the
nearest millimeter at baseline using a stadiometer165. Weight was measured with a
calibrated scaled, while wearing light street clothes, and recorded to the nearest 0.05
kg165. For this study, percentage weight loss was used to assess weight loss.
Percentage weight loss was calculated as:
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𝑊𝑒𝑖𝑔ℎ𝑡 𝑙𝑜𝑠𝑠 % =

𝑊𝑒𝑖𝑔ℎ (6 𝑚𝑜𝑛𝑡ℎ𝑠) − 𝑊𝑒𝑖𝑔ℎ𝑡(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)
∗ 100%
𝑊𝑒𝑖𝑔ℎ𝑡 (𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)

Dietary intake
Looking at participant dietary intake, three random 24-hour dietary recalls were
collected by phone during a 1 week period at 0 and 6 months. Recalls were conducted
by interviewers from the Cincinnati Center for Nutritional Research and Analysis trained
and blinded to the intervention and interventions assignment 165.
The Nutrition Data System Software for Research developed by the Nutrition
Coordinating Center, University of Minnesota, Minneapolis, MN was used to collect and
analyze the 3-day food records. The multiple-pass method was used to collect the data.
There are 5 phases for this method of recall of dietary data. In the first phase, the
participant tells the reviewer all of foods and beverages that were consumed. The
second phase occurs when the reviewer reviews the list with the participant. In the third
phase, the interviewer receives detailed information of the foods and beverages
consumed. In the fourth phase, participants were given 2-dimensional models of food
portions sizes to assist with accurate reporting. In the fifth phase the reviewer reviews
the entered information with the participants to ensure completeness.
Variables for dietary intake were calculated as means of the three days.
Variables include VA as Total Vitamin A Activity International Units, Beta Carotene
provitamin A carotenoid, Total Vitamin A Activity Retinol Equivalents, Beta Crytoxanthin
provitamin A Carotenoid, Alpha Carotene provitamin A carotenoid.
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4.2.4 Statistics
Independent t-tests and chi-squared tests were conducted to compare
demographics and anthropometrics measures between participants included in the
secondary data analyses and those not included. A significant difference was found
between those included and those not included in the analyses for education, which
was entered as a covariate in the remaining analyses.
For participants included in this secondary analysis, independent t-tests and chisquared tests were used to compare demographics and baseline anthropometrics, and
baseline dietary intake of selected VA variables between those who had successful
weight loss at 6 months and those who did not have successful weight loss at 6 months.
No significant differences were found between the two groups for baseline measures.
To determine if there was a significant difference in the amount of dietary VA
consumed at 6 months between participants with successful weight loss and
participants who did not have successful weight loss, a mixed analysis of covariance
(ANCOVA) was conducted, with weight loss % (10% weight loss at 6 months and less
than 10% weight loss at 6 months) as the between-subjects variable and time (6
months) as the within-subjects variable, and education as a covariate.
All analyses were conducted using SPSS Statistics 22.0, with alpha level set at
0.05.
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4.3 Results
Baseline participant characteristics
Baseline characteristics for those included in the analyses (n= 113) compared to
those that were excluded from the analyses (n=89) are shown below in Table 4. No
significant difference was found in weight, BMI, gender, race, ethnicity, marital status,
age, and group assignment. A significant difference was found between these groups
for education, with those included in the analyses having a higher percentage of having
some college education or higher than those not included in the analyses (91.2 % vs.
83.1 %). Therefore, education was entered as a covariate in all subsequent analyses.
Baseline characteristics for the successful weight loss and unsuccessful weight
loss groups are shown in Table 5 below. Participants were 51.9 ± 8.8 years,
predominately white (94.7%), female (59.6%), with some college education (91.2%),
married (75.2%) and not Hispanic (100%), and were obese (BMI = 35.0 ± 4.5). No
significant differences were detected for baseline characteristics and self-reported
dietary intake of VA between the groups.
Comparison of self-reported dietary intake of VA at 6 months between groups
There was no significant difference found for self-reported dietary intake of any of
the VA variables at 6 months between participants with successful weight loss and
participants with unsuccessful weight loss. See Table 6 below for comparison of means
of dietary VA variable values for participants.

53
Table 4 Baseline characteristics for participants included vs. those not included in
secondary analyses
Variable

Not Included (n=89)

Included (n=113)

Age (y)

51.9 ± 8.8

51.9 ± 8.8

Weight (lb)

218.9 ± 38.1

223.3 ± 40.2

BMI (kg/m2)

34.4 ± 3.9

35.0 ± 4.5

Female (%)

55.1

59.3

White (%)

88.8

94.7

Non-Hispanic (%)

98.9

100

Some college education or higher (%)*

83.1

91.2

Married (%)

71.9

75.2

Lifestyle assignment (%)

48.3

52.2

Note: *Significant at p<0.5
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Table 5 Baseline characteristics and self-reported dietary intake of vitamin A for
participants with successful weight loss and participants with unsuccessful weight loss
(M± SD)
Variable

Successful

Unsuccessful

weight loss (n =

weight loss (n

66)

= 47)

Age (y)

53.3 ±8.3

50.0 ±9.2

Weight (lb)

220.6 ± 40.6

227 ± 39.8

BMI (kg/m2)

34.7 ± 4.6

35.5 ± 4.4

Female (%)

59.1

59.6

White (%)

93.9

95.7

Non-Hispanic (%)

100

100

Some college education or higher (%)*

92.4

89.4

Married (%)

70.0

83.0

Lifestyle assignment (%)

48.5

57.4

Beta Carotene provitamin A carotenoid

3724.0 ± 2984.2

2815.6 ±

(mcg)
Total Vitamin A Activity Retinol Equivalents

2632.9
1304.6 ± 770.9

(mcg)
Total Vitamin A Activity Retinol Activity

528.8
959.0 ± 571.2

Equivalents (mcg)
Beta Crytoxanthin provitamin A carotenoid

149.0 ± 175.5

(IU)

97.8 ±
110.8

692.7 ± 737.7

(mcg)
Total Vitamin A Activity International Units

748.5 ±
362.4

(mcg)
Alpha Carotene provitamin A carotenoid

1006.9 ±

472.8 ±
511.5

8956.2 ± 5897.4

6802.5 ±
4692.8

Note: y-years old; lb- pounds; kg-kilograms; m- meters; mcg-microgram; IUInternational Units
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Table 6 Comparison of means of dietary vitamin A between participants with successful
10% weight loss and participants with less than 10% weight loss (M± SD)
Variable

Successful weight

Unsuccessful

loss (n = 66)

weight loss (n
= 47)

Beta Carotene provitamin A carotenoid

3625.54± 3094.07

(mcg)
Total Vitamin A Activity Retinol Equivalents

3109.14±
3171.55

1022.07± 579.31

989.20± 590.79

688.91± 341.65

701.83± 364.68

124.28± 125.26

122.48± 119.17

619.82± 595.45

555.37± 556.15

7848.80± 5501.16

7129.18±

(mcg)
Total Vitamin A Activity Retinol Activity
Equivalents (mcg)
Beta Crytoxanthin provitamin A carotenoid
(mcg)
Alpha Carotene provitamin A carotenoid
(mcg)
Total Vitamin A Activity International Units
(IU)

Note: mcg- microgram; IU- International Units

5542.82
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4.4 Discussion
The purpose of this investigation was to examine the relationship between
dietary VA and weight loss in participants in a lifestyle intervention. This was
accomplished by comparing the amount of VA consumed between participants who
successfully lost 10% weight and those who did not while consuming a hypocaloric, lowfat diet. Since no significant difference was detected in amount of VA consumed
between the groups, the results indicate that the amount of VA consumed in a weight
loss intervention where participants are experiencing a negative energy balance and
restricting fat did not have a relationship with weight loss.
There is limited human research investigating the effect of VA on obesity and the
previous research on the relationship between VA intake and obesity in humans has
mostly focused on the effects of excessive VA intake, and VA influence on weight gain,
rather than loss105,117-118. There is a need for further investigation on how VA intake
impacts weight loss.
In contrast to the first experiment for this thesis project, this experiment used a
human model where the goal for the participants was weight loss rather than weight
gain, as seen in the animal experiment. The diets also differed in that the participants
were instructed to follow a hypocaloric, low-fat diet as opposed to the obesogenic, highfat diet provided to the animal subjects. Dietary fat is essential for absorption of VA,
and restriction of fat may have played a role in the results of this experiment. Even if
participants consumed VA rich foods, if they did not also consume adequate fat, then
the VA would not have been absorbed to exert its physiological effects.
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One limitation of this study would be that the sample was homogenous in race
and ethnicity. Another limitation would be the use of self-reported dietary data. The
sample of those included in the analysis was also greatly reduced due to participants
being excluded from the analysis from lack of complete dietary data. Also, it is
important to note the large variation of average VA intake (based on a large standard
deviation) for participants in both groups. Additionally, since the study design was a
secondary data analysis conclusions on cause and effect cannot be made.
4.5 Conclusion
Our findings indicate that VA intake does not play a role in weight loss. Since the
weight loss intervention called for a restriction on fat intake, absorption of VA may have
been impacted. If VA absorption was impaired, it would not be able to carry out its
physiological activities.
It is important to note the contrast between the experiments used for this thesis
project. The first experiment used an animal model to examine the relationship
between VA intake and weight gain (obesity development) in HFD feeding conditions,
while the second experiment used a human model to look at the relationship between
VA intake and weight loss with a diet that was hypocaloric and low-fat. Even if the
results of the animal experiment indicate that VA plays a role in weight gain while
consuming an obesogenic HFD, this does not mean that VA plays a role in weight loss
when consuming a diet that is hypocaloric and low-fat. It is possible that fat content in
the diets for these experiments played a role in the results we have seen. The
relationship between VA intake and weight management may depend on the fat content
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of the diet. Another explanation for the results could be the negative energy balance
state used in this experiment. It is possible that VA does not influence weight
management when a hypocaloric diet is implemented.
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Chapter V
Discussion and Future Perspectives
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5.1 Conclusion
This thesis project incorporated two different models to investigate the impact of
VA in obesity. The first was an animal model, where animals were fed a high-fat diet
with the goal of weight gain during dietary treatment. The second model looked at
humans, where participants’ fat and energy intake were restricted with the goal of
achieving weight loss during the intervention. Because one model investigates weight
gain and the other investigates weight loss, two different models (weight loss and
weight gain), and two different diets (high-fat and low-fat) were examined.
We have known that vitamin A (VA) status affects plasma lipids levels, which is
supported by the results of the animal experiment. The current research on lipophilic
vitamin in high-fat diet (HFD) has focused mostly on the protective roles of lipophilic
vitamins in HFD feeding conditions. How HFD affects homeostasis of lipophilic vitamins
remains to be an open question. Knowing the essentiality of lipophilic vitamins for
general healthy, it can be easy to assume that their uptake is helpful in a variety of
dietary conditions. However, their uptakes share the same route as dietary lipids.
Mutual effects of dietary lipophilic vitamins and other lipid molecules on each other’s
digestions, absorption and functions may exists. Our current findings support the
assertion that VA status plays a key role in adiposity in HFD conditions. It is feasible to
assume that transport, storage and metabolism of these lipophilic vitamins alter with the
change of diets or metabolic states of a subject or population. Additional studies are
needed to understand the impacts of dietary components on the homeostasis of
lipophilic vitamins. Additional biochemical studies are need to analyze all the samples
collected. The expression levels of glucose and lipid metabolic enzymes in the
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metabolic active tissues and organs, such as the liver, adipose tissue and muscle will
certainly reveal the metabolic changes introduced by the elimination of VA in a diet of
high-fat setting.
Since our current findings showed no significant difference of VA intake between
participants who had successfully lost 10% weight and those who had not, this indicates
that intake of lipophilic vitamins was not related to weight loss. It has been established
that excessive VA intake can contribute to BM gain in participants without changes in
caloric intake, but it is not known if VA intake plays a role in weight loss when a
hypocaloric, low-fat diet is consumed. While the results of the animal experiment
indicate that VA plays a key role in weight gain in HFD conditions, the relationship (if
any) between VA intake, fat intake, and weight loss remains to be an open question.
Additional studies are needed to understand the role VA plays in the process of weight
loss. The amount of fat consumed could have affected the results of the current
experiment. Dietary fat is required for VA absorption. It is possible that the effects of
VA on weight management may depend on the fat content of the diet consume.
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